Kura Oncology (NASDAQ:KURA) Issues Earnings Results

Kura Oncology (NASDAQ:KURA) announced its quarterly earnings results on Thursday. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.03), Briefing.com reports. During the same period last year, the firm earned ($0.50) earnings per share. The company’s revenue for the quarter was up .0% compared to the same quarter last year.

Kura Oncology Stock Up 0.2 %

KURA opened at $20.63 on Friday. Kura Oncology has a fifty-two week low of $7.41 and a fifty-two week high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.26 and a quick ratio of 12.26. The company’s 50 day moving average price is $20.66 and its two-hundred day moving average price is $15.94.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Wedbush reiterated an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Friday. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Friday. JMP Securities increased their price target on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a “market outperform” rating in a research report on Wednesday, January 31st. Finally, StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $28.28.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.